Medicamen Biotech: SEBI Takeover Disclosure Filed
Under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 31(4) requires disclosure to the exchange when a substantial acquisition threshold is crossed or a takeover offer is contemplated. This filing indicates Medicamen Biotech is subject to such a transaction. The full disclosure document, held in the NSE archives, would contain details of the acquirer, shareholding pattern, consideration and regulatory approvals required.
Why it mattersMandatory Regulation 31(4) disclosure triggers strict timing and transparency obligations; the target must await regulator clearance and completion conditions before announcing material details.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives – Medicamen Biotech SEBI Takeover Disclosure Filing · official
- SEBI – Substantial Acquisition of Shares and Takeovers Regulations, 2011 · official
- Bar & Bench – Primary Article Reference · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026